Tipranavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

HIV

• Adults: 500 mg Tipranavir, co-administered with 200 mg ritonavir, twice daily. 
• Pediatric patients (age 2 to 18 years): Dosing is based on body weight or body surface area not to exceed adult dose. 
• Tipranavir taken with ritonavir capsules or solution can be taken with or without meals.
• Tipranavir taken with ritonavir tablets must be taken with meals.
• Store unopened bottles of Tipranavir capsules in the refrigerator.
• Do not freeze or refrigerate Tipranavir oral solution.

The most frequently reported adverse drug reactions were-

• diarrhea
• nausea
• vomiting
• abdominal pain 
• fever
• headache
• fatigue/asthenia

Diarrhea

Nausea

Fever

Fatigue

• Discontinue if you have clinical hepatitis or asymptomatic increases in ALT/AST >10 times the upper limit of normal or asymptomatic increases in ALT/AST 5-10 times the upper limit of normal with concomitant increases in total bilirubin. Prior to starting therapy, and on a regular basis afterwards, have liver function tests performed.
• Use with caution in patients who are at high risk of bleeding or who are taking medications that increase the risk of bleeding.
• Consider the potential for drug-drug interactions to reduce the risk of serious or life-threatening adverse reactions.
• If a severe skin reaction occurs or is suspected, discontinue and begin appropriate treatment. In patients who have a known sulfonamide allergy, use with caution.
• Diabetes mellitus, hyperglycemia, immune reconstitution syndrome, redistribution/accumulation of body fat, and elevated lipids may occur in patients.  Monitor cholesterol and triglycerides prior to therapy and periodically thereafter.
• Spontaneous bleeding may occur, and additional factor VIII may be required.